BeOne Medicines Ltd.
BEIGF$40.93B
Large CapNASDAQBiotechnology🇺🇸North America11.0K employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Sep 2026
Market Overview
Stock performance and key metrics
BEIGF News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Sonrotoclax
Waldenstrom Macroglobulinemia
Zanubrutinib
Chronic Lymphocytic Leukemia
BGB-16673
B-cell Malignancy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonrotoclax | Phase 3 | Waldenstrom Macroglobulinemia | - | - |
Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
BGB-16673 | Phase 2 | B-cell Malignancy | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply